Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3042]

Lower-dose radiation safe for certain lower-risk, HPV-positive head and neck...

Prof Anthony Cmelak - Vanderbilt-Ingram Cancer Center, Nashville, USA

Lower-dose radiation safe for certain lower-risk, HPV-positive head and neck cancers ( Prof Anthony Cmelak - Vanderbilt-Ingram Cancer Center, Nashville, USA )

ASCO 2014 roundup

Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy

ASCO 2014 roundup ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )

Lapatinib not found to be beneficial in head and neck cancer with high risk of...

Prof Kevin Harrington - Institute of Cancer Research, London, UK

Lapatinib not found to be beneficial in head and neck cancer with high risk of recurrence ( Prof Kevin Harrington - Institute of Cancer Research, London, UK )

Addition of docetaxel to initial hormone therapy substantially improves...

Dr Michael Carducci - Johns Hopkins School of Medicine, Baltimore, USA

Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer ( Dr Michael Carducci - Johns Hopkins School of Medicine, Baltimore, USA )

T-VEC injections into melanoma lesions show significant response rate

Prof Kevin Harrington - Institute of Cancer Research, London, UK

T-VEC injections into melanoma lesions show significant response rate ( Prof Kevin Harrington - Institute of Cancer Research, London, UK )

Adding lapatinib to adjuvant trastuzumab does not improve outcomes in early...

Dr Edith Perez - Mayo Clinic, Rochester, USA

Adding lapatinib to adjuvant trastuzumab does not improve outcomes in early- stage HER2-positive breast cancer ( Dr Edith Perez - Mayo Clinic, Rochester, USA )

Addition of docetaxel to initial hormone therapy substantially improves...

Prof Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA

Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer ( Prof Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA )

First-line bevacizumab plus chemo and cetuximab plus chemo provide similar...

Dr Alan Venook; Prof Gordon McVie

First-line bevacizumab plus chemo and cetuximab plus chemo provide similar survival benefits in metastatic colorectal cancer ( Dr Alan Venook; Prof Gordon McVie )

Comment: Advances in lung cancer presented at ASCO 2014

Prof Jacek Jassem - Gdańsk Medical University, Gdańsk, Poland

Comment: Advances in lung cancer presented at ASCO 2014 ( Prof Jacek Jassem - Gdańsk Medical University, Gdańsk, Poland )

Medyczne nowości w raku gruczołu krokowego

Prof Piotr Jan Wysocki - Poznan University of Medical Sciences, Poznan, Poland

Medyczne nowości w raku gruczołu krokowego ( Prof Piotr Jan Wysocki - Poznan University of Medical Sciences, Poznan, Poland )

Targeted drug combo, cediranib plus olaparib, significantly increases...

Dr Joyce Liu - Dana-Farber Cancer Institute, Boston, USA

Targeted drug combo, cediranib plus olaparib, significantly increases progression-free survival in recurrent ovarian cancer ( Dr Joyce Liu - Dana-Farber Cancer Institute, Boston, USA )

Upcoming trends in myeloma therapy

Dr Kenneth Anderson; Prof Gareth Morgan; Prof Paul Richardson

Upcoming trends in myeloma therapy ( Dr Kenneth Anderson; Prof Gareth Morgan; Prof Paul Richardson )

More from ecancer